DexCom (DXCM) Given a $150.00 Price Target at Oppenheimer

Oppenheimer set a $150.00 price objective on DexCom (NASDAQ:DXCM) in a report released on Wednesday morning. The firm currently has a buy rating on the medical device company’s stock. Oppenheimer also issued estimates for DexCom’s Q4 2018 earnings at $0.16 EPS, FY2018 earnings at ($0.10) EPS and FY2019 earnings at $0.25 EPS.

DXCM has been the subject of several other reports. BMO Capital Markets lifted their target price on shares of DexCom to $112.00 and gave the company an outperform rating in a report on Tuesday, July 10th. BidaskClub lowered shares of DexCom from a strong-buy rating to a buy rating in a report on Tuesday, September 18th. Raymond James lifted their target price on shares of DexCom from $125.00 to $150.00 and gave the company an outperform rating in a report on Tuesday, October 23rd. Bank of America lifted their target price on shares of DexCom from $106.00 to $127.00 and gave the company a buy rating in a report on Thursday, August 2nd. Finally, Berenberg Bank raised shares of DexCom from a hold rating to a buy rating and set a $140.00 target price for the company in a report on Monday, August 6th. Seven research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $132.50.

NASDAQ DXCM traded up $1.05 on Wednesday, hitting $149.46. 1,594,508 shares of the company’s stock traded hands, compared to its average volume of 1,254,658. The company has a current ratio of 4.71, a quick ratio of 4.62 and a debt-to-equity ratio of 0.60. DexCom has a 1-year low of $49.80 and a 1-year high of $152.14. The stock has a market cap of $12.85 billion, a price-to-earnings ratio of -257.69 and a beta of 0.60.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.12) by $0.29. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. The firm’s revenue was up 44.5% on a year-over-year basis. Analysts forecast that DexCom will post -0.22 EPS for the current year.

In other news, Director Steven R. Altman sold 2,500 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $135.65, for a total transaction of $339,125.00. Following the transaction, the director now owns 3,449 shares of the company’s stock, valued at approximately $467,856.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Steven Robert Pacelli sold 3,114 shares of the business’s stock in a transaction dated Tuesday, October 23rd. The shares were sold at an average price of $128.85, for a total transaction of $401,238.90. The disclosure for this sale can be found here. Insiders have sold 157,892 shares of company stock valued at $21,864,030 in the last ninety days. Insiders own 1.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Canada Pension Plan Investment Board boosted its position in shares of DexCom by 141.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 238,728 shares of the medical device company’s stock valued at $34,148,000 after acquiring an additional 140,028 shares during the last quarter. Artemis Investment Management LLP acquired a new position in shares of DexCom during the 3rd quarter valued at about $9,663,000. Crossmark Global Holdings Inc. acquired a new position in shares of DexCom during the 3rd quarter valued at about $264,000. Piedmont Investment Advisors Inc. acquired a new position in shares of DexCom during the 3rd quarter valued at about $904,000. Finally, Swiss National Bank boosted its position in shares of DexCom by 1.0% during the 3rd quarter. Swiss National Bank now owns 153,600 shares of the medical device company’s stock valued at $21,971,000 after acquiring an additional 1,500 shares during the last quarter.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply